MRI/US融合引导活检:仅行靶向穿刺用于前列腺癌早期检测
研究纳入108例临床怀疑前列腺癌(PSA>4 ng/mL)的男性,行多参数MRI后对PIRADS 4/5病灶行MRI/US融合引导靶向穿刺,PIRADS 3者随访。作者认为仅行靶向融合穿刺可提高临床显著癌检出率。
要点
- PSA>4 ng/mL且mpMRI显示PIRADS 4/5病灶者,仅行MRI/US融合引导靶向穿刺,总体癌症检出率63%。
- mpMRI为PIRADS 3的17例未行穿刺,采用系列PSA、临床再评估和随访mpMRI。
核心结论
- 对PSA>4 ng/mL的临床怀疑前列腺癌患者,仅行MRI/US融合引导靶向穿刺可提高临床显著癌检出率,并改变治疗选择和预后。
研究设计与样本
- 单臂诊断性研究,纳入108例年龄46-78岁、临床怀疑前列腺癌(PSA>4 ng/mL)的男性,行前列腺多参数MRI,对PIRADS v2评分可疑病灶行MRI/US融合引导靶向穿刺,以病理为参考标准。
关键影像表现/征象
- 91/108例mpMRI显示高度可疑病灶(PIRADS 4和5),其余17/108例无显著异常(PIRADS 3)。
- PIRADS 4/5组中58/91例病理证实前列腺癌,33例阴性。
诊断标准与关键数值
- 总体癌症检出率为63%。
- 58例阳性中Gleason评分6(3+3)24例,Gleason评分7共18例(3+4者7例、4+3者11例),Gleason评分8(4+4)14例,Gleason评分9(5+4)2例。
临床应用与阅片要点
- 对PSA>4 ng/mL且mpMRI显示PIRADS 4/5病灶者,可行MRI/US融合引导靶向穿刺作为诊断方式。
- PIRADS 3且无显著异常模式者,采用系列PSA评估、临床再评估和随访mpMRI。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The aim of this study was to validate the role of MR/Ultrasound Fusion-Guided Targeted Biopsy as a first diagnostic modality in subjects with clinical suspicion of prostate cancer (PCa).
MATERIALS AND METHODS: 108 men (age range 46-78 years) with clinical suspicion for PCa (PSA > 4 ng/mL) underwent multiparametric MRI of the prostate (mpMRI) and, when suspicious lesion were found (according to the PIRADSv2 scoring system), targeted biopsy was performed. All patients without significant alteration patterns at mpMRI have been referred for follow-up at 1 year.
RESULTS: 91/108 patients showed on the mpMRI highly suspicious lesions (PIRADS 4 and 5); the remaining 17/108 patients revealed no significant alteration consistent with PCa (PIRADS 3). Among the first group of patients, 58/91 proved to be positive for PCa on the pathology report: 24 patients had a Gleason Score (GS) 6 (3 + 3); 18 patients GS 7 of which 7 (3 + 4) and 11 (4 + 3); 14 patients GS 8 (4 + 4); two patients GS 9 (5 + 4); 33 proved to be negative. Overall cancer detection rate (CDR) was 63%. However, the CDR rises significantly, up to 77%, after the 53 initial consecutive biopsies that were performed (p < 0,05) and thus identified as part of the learning curve. Patients of the second group (17/108) have been followed with serial PSA assessments, clinical reevaluation, and follow-up mpMRI.
CONCLUSION: Performing exclusively targeted MR/Ultrasound Fusion-Guided biopsies for the diagnosis of PCa in patients with suspicious PSA levels (> 4 ng/mL) increases the detection rate of clinically significant cancer, changing both the therapeutic options and the prognosis.
引用
- Del Monte M, Leonardo C, Salvo V, et al. MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer. Radiol Med. 2017. PMID: 29075977. doi:10.1007/s11547-017-0825-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。